Trevi Therapeutics (TRVI) said late Tuesday topline data from a human abuse potential study shows that its oral nalbuphine drug candidate, aimed at the treatment of chronic cough, had statistically significant lower "drug liking" compared with butorphanol.
Drug liking is a measure of the pleasurable experience after consuming a drug, often used to study their misuse liability.
The company added, however, that the supratherapeutic dose of oral nalbuphine at 486 milligrams "was numerically lower" than the 6mg IV butorphanol for drug liking "but the results were not statistically significant."
The study did not observe any serious adverse events, the company said.
Shares of Trevi Therapeutics were down more than 13% in after-hours activity Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.